ClinicalTrialsFinder

Relapsed or Refractory NK/T-Cell Lymphoma Clinical Trials in Shanghai, Shanghai Municipality

1 recruitingShanghai, Shanghai Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma

Extranodal NK T Cell LymphomaNK/T-cell LymphomaRelapsed or Refractory NK/T-Cell Lymphoma
Rong Tao107 enrolled1 locationNCT07502768